Trade Pliant Therapeutics, Inc. - PLRX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.09 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.026235% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004012% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 11.83 |
| Open | 12.51 |
| 1-Year Change | -21.71% |
| Day's Range | 12.15 - 12.8 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 17, 2024 | 12.56 | 0.59 | 4.93% | 11.97 | 12.87 | 11.97 |
| Sep 16, 2024 | 11.83 | -0.43 | -3.51% | 12.26 | 12.26 | 11.49 |
| Sep 13, 2024 | 11.95 | 0.14 | 1.19% | 11.81 | 12.00 | 11.62 |
| Sep 12, 2024 | 11.79 | -0.43 | -3.52% | 12.22 | 12.31 | 11.73 |
| Sep 11, 2024 | 12.21 | -0.34 | -2.71% | 12.55 | 12.71 | 12.19 |
| Sep 10, 2024 | 12.94 | 0.06 | 0.47% | 12.88 | 13.07 | 12.61 |
| Sep 9, 2024 | 12.84 | -0.09 | -0.70% | 12.93 | 13.51 | 12.74 |
| Sep 6, 2024 | 12.84 | -0.30 | -2.28% | 13.14 | 13.45 | 12.52 |
| Sep 5, 2024 | 13.31 | 0.80 | 6.39% | 12.51 | 13.43 | 12.49 |
| Sep 4, 2024 | 12.78 | 0.24 | 1.91% | 12.54 | 12.89 | 12.38 |
| Sep 3, 2024 | 12.75 | -0.03 | -0.23% | 12.78 | 13.48 | 12.61 |
| Aug 30, 2024 | 13.25 | 0.14 | 1.07% | 13.11 | 13.32 | 12.84 |
| Aug 29, 2024 | 13.12 | 0.48 | 3.80% | 12.64 | 13.52 | 12.63 |
| Aug 28, 2024 | 12.85 | -0.03 | -0.23% | 12.88 | 13.10 | 12.68 |
| Aug 27, 2024 | 13.06 | 0.04 | 0.31% | 13.02 | 13.41 | 12.71 |
| Aug 26, 2024 | 13.42 | -0.03 | -0.22% | 13.45 | 13.53 | 13.26 |
| Aug 23, 2024 | 13.43 | 0.23 | 1.74% | 13.20 | 13.66 | 12.98 |
| Aug 22, 2024 | 13.18 | 0.06 | 0.46% | 13.12 | 13.65 | 13.04 |
| Aug 21, 2024 | 13.39 | -0.17 | -1.25% | 13.56 | 13.92 | 13.36 |
| Aug 20, 2024 | 13.86 | 0.85 | 6.53% | 13.01 | 14.03 | 12.97 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Pliant Therapeutics, Inc. Company profile
About Pliant Therapeutics Inc
Pliant Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. It focuses in treating fibrosis by inhibiting integrin-mediated activation of transforming growth factor beta (TGF-B). Its lead product candidate, PLN-74809, is an oral small-molecule, dual-selective inhibitor of avß6 and avB1. The Company’s second product candidate, PLN-1474, is a small-molecule, selective inhibitor of avB1 for treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition to its clinical programs, it is developing additional preclinical integrin-based programs. The first preclinical program is oncology program. Its second preclinical program is an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor being developed for treatment of muscular dystrophies, including duchenne muscular dystrophy.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Pliant Therapeutics Inc revenues decreased 82% to $7.6M. Net loss increased from $41.5M to $97.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase of 14% to $73.6M (expense), General and administrative - Balancing increase of 39% to $21M (expense).
| Industry: | Pharmaceuticals (NEC) |
260 Littlefield Avenue
Suite 150
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
News
Bank of Japan Preview
The Bank of Japan will meet on September 20, 2024, with markets anticipating minimal policy changes. However, inflation risks remain, with core CPI at 2.7% and potential for future interest rate hikes.
09:40, 17 September 2024
FOMC Decision Preview
As the US Federal Reserve prepares for its most significant decision since ending the rate hike cycle in mid-2023, the balance of risks has shifted. With inflation stabilizing at 2.6% and rising unemployment at 4.2%, the FOMC faces increasing pressure to address employment concerns. Markets anticipate a rate cut, with debate on the extent of the reduction.
09:48, 16 September 2024
ECB Preview: cuts expected but the pace is uncertain
Markets expect the ECB to cut rates again in September, but how many more?
12:34, 11 September 2024
Market analysis: US CPI and PPI
Overview of upcoming US inflation data for August, with expectations for a year-over-year CPI drop to 2.6% and core CPI holding steady at 3.2%. Markets will also focus on U.S. PPI data, which is forecasted to show mild growth, reinforcing potential easing inflationary pressures.
07:56, 10 September 2024
Introducing Newsquawk: your new in-platform newsfeed
We are very excited to announce the launch of Newsquawk in the Capital.com platform and app. This new newsfeed is designed to help you get ahead with real-time headlines, personalised stories and in-depth reports – all available directly in the platform and app, where you need them.
14:09, 20 August 2024
Jackson Hole Preview: All eyes on Powell and Gold
The key focus this week will be on Jerome Powell and any insight he may give into the future of monetary policy.
15:24, 19 August 2024
All eyes on inflation: US and UK CPI take centre stage
Just over a month has gone by since the latest CPI data was released in the US and so much has happened since.
14:41, 13 August 2024People also watch
Still looking for a broker you can trust?
Join the 640,000+ traders worldwide that chose to trade with Capital.com